Recently published data, analyzing 16 patients with early breast cancer and 16 patients with metastatic breast cancer with immunocytochemical double staining, demonstrated that CTCs express receptors and activating signaling kinases of the EGFR/HER2/PI3K/Akt pathway, which could be used as targets for their effective elimination [38]. The gene discussed is EGFR; the disease is breast cancer.